SCHEMBL24254514

SCHEMBL24254514

CCc1ccc(S(=O)(=O)N(C)C)cc1N

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
POLB P06746 2/20 0.54
PKM P14618 1/20 0.54
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 2/20 0.44
MAPT P10636 1/20 0.44
TNF P01375 1/20 0.44
RAB9A P51151 1/20 0.44
NOD1 Q9Y239 1/20 0.44
KDM4E B2RXH2 3/20 0.42
HTR2C P28335 1/20 0.42
HTR2B P41595 1/20 0.42
VCAM1 P19320 1/20 0.42
LOX P28300 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL914479 0.82 ALDH1A1 (0.64) ALDH1A1MEN1KMT2APOLBPKM
SCHEMBL1503399 0.80 GAA (0.55) ALDH1A1MEN1KMT2APOLBPKM
SCHEMBL6265475 0.79 ALDH1A1 (0.56) ALDH1A1MEN1KMT2APOLBPKM
SCHEMBL1371001 0.79 G6PD (0.53) MEN1KMT2APOLBPKMHTT
SCHEMBL23057070 0.78 ALDH1A1 (0.54) ALDH1A1MEN1KMT2APOLBPKM
SCHEMBL11101277 0.78 VCAM1 (0.58) ALDH1A1MEN1KMT2APOLBPKM
SCHEMBL24196436 0.78 ALDH1A1 (0.54) ALDH1A1MEN1KMT2APOLBPKM
SCHEMBL6937115 0.78 MAPT (0.63) ALDH1A1MEN1KMT2APOLBPKM
SCHEMBL16306950 0.77 VCAM1 (0.43) ALDH1A1MEN1KMT2APOLBPKM
SCHEMBL14374413 0.77 MAPT (0.64) ALDH1A1KMT2APOLBPKMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 ALDH1A1 1387/4885MEN1 3058/4885KMT2A 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.